BioNTech SE

BNTX

Equity

ISIN null / Valor 50030055

NASDAQ (2025-12-26)

USD 94.52-0.54%

BioNTech SE
UMushroom community rating:

3.40 4 votes No rating yet

NegativeNeutralPositive

About company

BioNTech SE is a biotechnology company focused on improving global health through the research and development of immunotherapies. Founded by scientists and physicians, the company is dedicated to translating scientific advancements into life-saving treatments by leveraging a diverse toolbox of drug classes and platform technologies, including mRNA-based therapies, cell therapies, small molecules, antibodies, and other protein-based therapies. BioNTech's innovative approach aims to provide personalized and effective treatments for patients worldwide, with a particular focus on developing novel cell therapies for targeting cancer-specific antigens, such as chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) programs. Additionally, the company is exploring the combination of mRNA FixVac platform with CAR T product candidates to enhance the persistence of CAR-T cells in vivo.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-16.9%1Y

-46.3%3Y

-2.52%5Y

Performance

49.3%1Y

43.0%3Y

58.5%5Y

Volatility

22728 M

Market cap (USD)

503,598

Daily traded volume (Shares)

114.24 / 110.81

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.40

4 votes

Performance:

3.00

Innovation:

3.50

Society:

3.10

Nature:

3.00

Tommy Ebneter

Switzerland, 14 Apr 2025

Spannende, zukunftsorientierte Aktie mit hohem Potenzial – aber auch erhöhtem Risiko. Besonders interessant für langfristige und forschungsaffine Anleger.